BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.) Tel. 0731-2723016; Email id- bcplcompliance@gmail.com; Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 13th August, 2024

To,	То,
The Secretary (DCS/Compliance),	The Secretary (Listing/Compliance),
Corporate Relationship Department,	Corporate Relationship Department,
BSE Limited	National Stock Exchange of India Limited,
Phiroze Jeejeebhoy Towers,	Exchange Plaza, C-1, Block G, Bandra Kurla
Dalal Street, Mumbai-400001	Complex, Mumbai – 400051

Subject: Continuous disclosure under sub-para 1 of Para A of Part A of Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023

Reference: Biofil Chemicals & Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 regarding continuous disclosure requirement for listed entities, we are enclosing disclosure as required under sub-para 1 of Para A of Part A of Schedule III regarding entering in to agreement for sell, transfer or otherwise dispose the whole of the undertaking of the Company situated at 11/12, Sector 'E', Sanwer Road Industrial Area, Indore – 452015 Madhya Pradesh including Leasehold land right, plant & machineries, furniture, fixtures, scraps, structure, tools, manufacturing equipments and other assets, considering it to be material event.

The Meeting of the Board of Directors commenced at 05.00 P.M. and concluded at 06.20 P.M.

The above information will also be available on the website of the Company at www.biofilgroup.net.

This is for your information and record.

Thanking you, Yours faithfully,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

RAMESH SHAH CHAIRMAN AND MANAGING DIRECTOR DIN: 00028819 CONTINUOUS DISCLOSURE UNDER SUB-PARA 1 OF PARA A OF PART A OF SCHEDULE III PURSUANT TO REGULATION 30 OF THE SEBI (LODR) REGULATION, 2015 READ WITH SEBI CIRCULAR SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED 13TH JULY, 2023

ENTERING IN TO AGREEMENT FOR SELL, TRANSFER OR OTHERWISE DISPOSE THE WHOLE OF THE UNDERTAKING SITUATED AT 11/12, SECTOR 'E', SANWER ROAD INDUSTRIAL AREA, INDORE – 452015 MADHYA PRADESH

Α	the amount and percentage of the turnover or	Turnover of INR 2786.78 Lacs
	revenue or income and net worth contributed	Undertaking
	by such unit or division or undertaking or	Percentage of total 69.61%
	subsidiary or associate company of the listed	turnover contributed
	entity during the last financial year;	by Undertaking
		Net worth INR 932.67 Lacs
		contributed by
		Undertaking
		Percentage of total 64.81%
		Net worth
		contributed by
		Undertaking
В	date on which the agreement for sale has been	Company has entered into sale agreement on
	entered into;	13 th August, 2024 for sell, transfer or otherwise
		dispose the whole of the undertaking of the
		Company situated at 11/12, Sector 'E', Sanwer
		Road Industrial Area, Indore – 452015 Madhya Pradesh including Leasehold land right, plant &
		machineries, furniture, fixtures, scraps,
		structure, tools, manufacturing equipments and
		other assets
С	the expected date of completion of	The expected completion date is on or before
	sale/disposal;	March 31st, 2025 subject to approval of
		shareholders in ensuing annual general meeting.
D	consideration received from such	The amount of sale consideration will be INR
	sale/disposal;	4.12 Crore and shall be executed after approval
		from shareholder in ensuing annual general
		meeting.
E	Brief details of buyers and whether any of the	The sale agreement is entered into with Cyano
	buyers belong to the promoter/promoter group/group companies. If yes, details thereof;	Pharma Private Limited (Group Company)
	group/group companies. If yes, details thereof;	having registered office at 6 Gr. Floor, Patnawala Compound, Opp. Shreyas LBS Marg, Ghatkopar
		(W) Mumbai City MH 400086 and factory
		situated at 115-C, Industrial Estate, Pologround
		Indore 452015 and also related to the promoter
		and promoter group of the company.
F	Whether the transaction would fall within	Yes, the transaction would fall under a related
	related party transactions? If yes, whether the	party transaction and it will be carried out on an
	same is done at "arm's length";	arm's length basis.
G	Whether the sale, lease or disposal of the	Not applicable
	undertaking is outside Scheme of	
	Arrangement? If yes, details of the same	Further the company has already obtained
	including compliance with regulation 37A of	member's approval through a special resolution
	LODR Regulations.	passed using postal ballot mechanism on March
		15th, 2024 and also in compliance with
		regulation 37A of LODR Regulation.

Н	Additionally, in case of a slump sale, indicative	
	disclosures provided for	N.A.
	amalgamation/merger, shall be disclosed by	
	the listed entity with respect to such slump	
	sale.	

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

RAMESH SHAH CHAIRMAN AND MANAGING DIRECTOR DIN: 00028819